Annual EBITDA
-$67.00 M
-$948.00 K-1.44%
31 December 2023
Summary:
Inozyme Pharma annual earnings before interest, taxes, depreciation & amortization is currently -$67.00 million, with the most recent change of -$948.00 thousand (-1.44%) on 31 December 2023. During the last 3 years, it has fallen by -$10.18 million (-17.91%). INZY annual EBITDA is now -479.26% below its all-time high of -$11.57 million, reached on 31 December 2018.INZY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$22.96 M
+$2.49 M+9.79%
30 September 2024
Summary:
Inozyme Pharma quarterly earnings before interest, taxes, depreciation & amortization is currently -$22.96 million, with the most recent change of +$2.49 million (+9.79%) on 30 September 2024. Over the past year, it has dropped by -$7.48 million (-48.34%). INZY quarterly EBITDA is now -433.93% below its all-time high of -$4.30 million, reached on 30 September 2019.INZY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$90.30 M
-$7.48 M-9.03%
30 September 2024
Summary:
Inozyme Pharma TTM earnings before interest, taxes, depreciation & amortization is currently -$90.30 million, with the most recent change of -$7.48 million (-9.03%) on 30 September 2024. Over the past year, it has dropped by -$25.89 million (-40.20%). INZY TTM EBITDA is now -1655.16% below its all-time high of -$5.14 million, reached on 31 March 2019.INZY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INZY EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.4% | -48.3% | -40.2% |
| 3 y3 years | -17.9% | -62.9% | -86.0% |
| 5 y5 years | -479.3% | -433.9% | -546.0% |
INZY EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -19.7% | at low | -62.9% | +9.8% | -86.0% | at low |
| 5 y | 5 years | -479.3% | at low | -433.9% | +18.8% | -546.0% | at low |
| alltime | all time | -479.3% | at low | -433.9% | +18.8% | -1655.2% | at low |
Inozyme Pharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$22.96 M(-9.8%) | -$90.30 M(+9.0%) |
| June 2024 | - | -$25.45 M(+16.5%) | -$82.82 M(+15.1%) |
| Mar 2024 | - | -$21.84 M(+8.9%) | -$71.97 M(+7.4%) |
| Dec 2023 | -$67.00 M(+1.4%) | -$20.05 M(+29.6%) | -$67.00 M(+4.0%) |
| Sept 2023 | - | -$15.48 M(+6.0%) | -$64.41 M(-1.9%) |
| June 2023 | - | -$14.60 M(-13.4%) | -$65.65 M(-0.9%) |
| Mar 2023 | - | -$16.87 M(-3.4%) | -$66.26 M(+0.3%) |
| Dec 2022 | -$66.06 M(+18.0%) | -$17.46 M(+4.4%) | -$66.06 M(-1.7%) |
| Sept 2022 | - | -$16.72 M(+9.9%) | -$67.17 M(+4.1%) |
| June 2022 | - | -$15.21 M(-8.7%) | -$64.54 M(+4.4%) |
| Mar 2022 | - | -$16.66 M(-10.3%) | -$61.82 M(+10.4%) |
| Dec 2021 | -$55.97 M | -$18.57 M(+31.8%) | -$55.97 M(+15.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$14.10 M(+12.9%) | -$48.55 M(-22.6%) |
| June 2021 | - | -$12.49 M(+15.5%) | -$62.72 M(+5.0%) |
| Mar 2021 | - | -$10.81 M(-3.0%) | -$59.76 M(+5.2%) |
| Dec 2020 | -$56.82 M(+174.2%) | -$11.15 M(-60.6%) | -$56.82 M(+8.4%) |
| Sept 2020 | - | -$28.27 M(+196.9%) | -$52.42 M(+84.3%) |
| June 2020 | - | -$9.52 M(+20.8%) | -$28.45 M(+21.3%) |
| Mar 2020 | - | -$7.88 M(+16.9%) | -$23.46 M(+13.2%) |
| Dec 2019 | -$20.72 M(+79.2%) | -$6.74 M(+56.8%) | -$20.72 M(+48.2%) |
| Sept 2019 | - | -$4.30 M(-5.2%) | -$13.98 M(+44.4%) |
| June 2019 | - | -$4.53 M(-11.9%) | -$9.68 M(+88.1%) |
| Mar 2019 | - | -$5.14 M | -$5.14 M |
| Dec 2018 | -$11.57 M | - | - |
FAQ
- What is Inozyme Pharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Inozyme Pharma?
- What is Inozyme Pharma annual EBITDA year-on-year change?
- What is Inozyme Pharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Inozyme Pharma?
- What is Inozyme Pharma quarterly EBITDA year-on-year change?
- What is Inozyme Pharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Inozyme Pharma?
- What is Inozyme Pharma TTM EBITDA year-on-year change?
What is Inozyme Pharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of INZY is -$67.00 M
What is the all time high annual EBITDA for Inozyme Pharma?
Inozyme Pharma all-time high annual earnings before interest, taxes, depreciation & amortization is -$11.57 M
What is Inozyme Pharma annual EBITDA year-on-year change?
Over the past year, INZY annual earnings before interest, taxes, depreciation & amortization has changed by -$948.00 K (-1.44%)
What is Inozyme Pharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of INZY is -$22.96 M
What is the all time high quarterly EBITDA for Inozyme Pharma?
Inozyme Pharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$4.30 M
What is Inozyme Pharma quarterly EBITDA year-on-year change?
Over the past year, INZY quarterly earnings before interest, taxes, depreciation & amortization has changed by -$7.48 M (-48.34%)
What is Inozyme Pharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of INZY is -$90.30 M
What is the all time high TTM EBITDA for Inozyme Pharma?
Inozyme Pharma all-time high TTM earnings before interest, taxes, depreciation & amortization is -$5.14 M
What is Inozyme Pharma TTM EBITDA year-on-year change?
Over the past year, INZY TTM earnings before interest, taxes, depreciation & amortization has changed by -$25.89 M (-40.20%)